GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Consun Pharmaceutical Group Ltd (HKSE:01681) » Definitions » Capex-to-Operating-Cash-Flow

Consun Pharmaceutical Group (HKSE:01681) Capex-to-Operating-Cash-Flow : 0.06 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Consun Pharmaceutical Group Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Consun Pharmaceutical Group's Capital Expenditure for the six months ended in Dec. 2023 was HK$-39.15 Mil. Its Cash Flow from Operations for the six months ended in Dec. 2023 was HK$617.98 Mil.

Hence, Consun Pharmaceutical Group's Capex-to-Operating-Cash-Flow for the six months ended in Dec. 2023 was 0.06.


Consun Pharmaceutical Group Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Consun Pharmaceutical Group's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Consun Pharmaceutical Group Capex-to-Operating-Cash-Flow Chart

Consun Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.47 0.06 0.14 0.05 0.06

Consun Pharmaceutical Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.08 0.04 0.07 0.06

Competitive Comparison of Consun Pharmaceutical Group's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Consun Pharmaceutical Group's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Consun Pharmaceutical Group's Capex-to-Operating-Cash-Flow falls into.



Consun Pharmaceutical Group Capex-to-Operating-Cash-Flow Calculation

Consun Pharmaceutical Group's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-57.493) / 895.775
=0.06

Consun Pharmaceutical Group's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-39.145) / 617.983
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Consun Pharmaceutical Group  (HKSE:01681) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Consun Pharmaceutical Group Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Consun Pharmaceutical Group's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Consun Pharmaceutical Group (HKSE:01681) Business Description

Traded in Other Exchanges
Address
71, Dongpeng Avenue, Eastern section, Guangzhou Economic and Technological Development, Guangzhou, CHN
Consun Pharmaceutical Group Ltd is a biotechnology company with sales operations throughout China. Its principal activities are making and selling pharmaceutical products. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Consun derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
Executives
An Yubao 2101 Beneficial owner
Li Qian 2101 Beneficial owner
Central Success Developments Limited 2101 Beneficial owner
Aali Resources Limited 2201 Interest of corporation controlled by you
Bos Trustee Limited 2301 Trustee
Zhang Lihua 2202 Interest of your spouse
An Meng 2101 Beneficial owner
Double Grace International Limited 2101 Beneficial owner
Bos Trustee Limited As Trustee 2201 Interest of corporation controlled by you

Consun Pharmaceutical Group (HKSE:01681) Headlines

No Headlines